Biologics in the management of psoriasis

References

• GreavesMWWeinsteinGDTreatment of psoriasisN Engl J Med199533295815887838193
   PubMed Web of Science ®Google Scholar
• LowesMABowcockAMKruegerJGPathogenesis and therapy of psoriasisNature2007445713086687317314973
   PubMed Web of Science ®Google Scholar
• JoblingRGPsoriasis: a preliminary questionnaire study of sufferers’ subjective experienceClin Exp Dermatol197613233236975604
   PubMed Web of Science ®Google Scholar
• KooJPopulation-based epidemiologic study of psoriasis with emphasis on quality of life assessmentDermatol Clin19961434854968818558
   PubMed Web of Science ®Google Scholar
• FriedRGFriedmanSParadisCTrivial or terrible? The psychosocial impact of psoriasisInt J Dermatol19953421011057737765
   PubMed Web of Science ®Google Scholar
• GuptaMAGuptaAKQuality of life of psoriasis patientsJ Eur Acad Dermatol Venereol200014424124211204506
   PubMed Web of Science ®Google Scholar
• Devrimci-OzguvenHKundakciTNKumbasarHBoyvatAThe depression, anxiety, life satisfaction and affective expression levels in psoriasis patientsJ Eur Acad Dermatol Venereol200014426727111204514
   PubMed Web of Science ®Google Scholar
• WahlALogeJHWiklundIHanestadBRThe burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population normsJ Am Acad Dermatol2000435 pt 180380811050584
   PubMed Web of Science ®Google Scholar
• LangleyRGKruegerGGGriffithsCEPsoriasis: epidemiology, clinical features, and quality of lifeAnn Rheum Dis200564Suppl 2ii1823
   Google Scholar
• FeldmanSRFleischerABJrReboussinDMThe economic impact of psoriasis increases with psoriasis severityJ Am Acad Dermatol19973745645699344194
   PubMed Web of Science ®Google Scholar
• ChaudhariURomanoPMulcahyLDDooleyLTBakerDGGottliebABEfficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trialLancet200135792711842184711410193
   PubMed Web of Science ®Google Scholar
• SternRSNijstenTFeldmanSRMargolisDJRolstadTPsoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfactionJ Investig Dermatol Symp Proc200492136139
   PubMed Web of Science ®Google Scholar
• HammingaEAvan der LelyAJNeumannHAThioHBChronic inflammation in psoriasis and obesity: implications for therapyMed Hypotheses200667476877316781085
   PubMed Web of Science ®Google Scholar
• NeimannALShinDBWangXMargolisDJTroxelABGelfandJMPrevalence of cardiovascular risk factors in patients with psoriasisJ Am Acad Dermatol200655582983517052489
   PubMed Web of Science ®Google Scholar
• SommerDMJenischSSuchanMChristophersEWeichenthalMIncreased prevalence of the metabolic syndrome in patients with moderate to severe psoriasisArch Dermatol Res2006298732132817021763
   PubMed Web of Science ®Google Scholar
• LebwohlMPsoriasisLancet200336193641197120412686053
   PubMed Web of Science ®Google Scholar
• WongKGladmanDDHustedJLongJAFarewellVTMortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of deathArthritis Rheum19974010186818729336423
   PubMed Web of Science ®Google Scholar
• GladmanDDFarewellVTWongKHustedJMortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for deathArthritis Rheum1998416110311109627021
   PubMed Web of Science ®Google Scholar
• KruegerJGThe immunologic basis for the treatment of psoriasis with new biologic agentsJ Am Acad Dermatol200246112311756941
   PubMed Web of Science ®Google Scholar
• WillkensRFWilliamsHJWardJRRandomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritisArthritis Rheum19842743763816712754
   PubMed Web of Science ®Google Scholar
• CleggDORedaDJMejiasEComparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative StudyArthritis Rheum19963912201320208961906
   PubMed Web of Science ®Google Scholar
• SalvaraniCMacchioniPOlivieriIA comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritisJ Rheumatol200128102274228211669169
   PubMed Web of Science ®Google Scholar
• PipitoneNKingsleyGHManzoAScottDLPitzalisCCurrent concepts and new developments in the treatment of psoriatic arthritisRheumatology (Oxford)200342101138114812810935
   PubMed Web of Science ®Google Scholar
• JonesGCrottyMBrooksPInterventions for psoriatic arthritisCochrane Database Syst Rev20003CD000212
   Google Scholar
• KaltwasserJPNashPGladmanDEfficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trialArthritis Rheum20045061939195015188371
   PubMed Web of Science ®Google Scholar
• SainiRTutroneWDWeinbergJMAdvances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimusCurr Pharm Des200511227328015638763
   PubMed Web of Science ®Google Scholar
• SchotteliusAJMoldawerLLDinarelloCAAsadullahKSterryWEdwardsCK3rdBiology of tumor necrosis factor-alpha- implications for psoriasisExp Dermatol200413419322215086336
   PubMed Web of Science ®Google Scholar
• KristensenMChuCQEedyDJFeldmannMBrennanFMBreathnachSMLocalization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptorClin Exp Immunol19939423543628222328
   PubMed Web of Science ®Google Scholar
• NickoloffBJKarabinGDBarkerJNCellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasisAm J Pathol199113811291401702929
   PubMed Web of Science ®Google Scholar
• UyemuraKYamamuraMFivensonDFModlinRLNickoloffBJThe cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated responseJ Invest Dermatol199310157017057693825
   PubMed Web of Science ®Google Scholar
• BonifatiCCarducciMCordiali FeiPCorrelated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients – relationships with disease severityClin Exp Dermatol19941953833877955493
   PubMed Web of Science ®Google Scholar
• EttehadiPGreavesMWWallachDAderkaDCampRDElevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesionsClin Exp Immunol19949611461518149659
   PubMed Web of Science ®Google Scholar
• MussiABonifatiCCarducciMSerum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasisJ Biol Regul Homeost Agents19971131151189498161
   PubMed Web of Science ®Google Scholar
• AricanOAralMSasmazSCiragilPSerum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severityMediators Inflamm20052005527327916258194
   PubMed Web of Science ®Google Scholar
• PartschGSteinerGLeebBFDunkyABröllHSmolenJSHighly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluidJ Rheumatol19972435185239058659
   PubMed Web of Science ®Google Scholar
• RitchlinCHaas-SmithSAHicksDCappuccioJOsterlandCKLooneyRJPatterns of cytokine production in psoriatic synoviumJ Rheumatol1998258154415529712099
   PubMed Web of Science ®Google Scholar
• DanningCLIlleiGGHitchonCGreerMRBoumpasDTMcInnesIBMacrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritisArthritis Rheum20004361244125610857783
   PubMed Web of Science ®Google Scholar
• AmeglioFBonifatiCPietravalleMFazioMInterleukin-6 and tumour necrosis factor levels decrease in the suction blister fluids of psoriatic patients during effective therapyDermatology199418943593637873820
   PubMed Web of Science ®Google Scholar
• OlaniranAKBakerBSPaigeDGGariochJJPowlesAVFryLCytokine expression in psoriatic skin lesions during PUVA therapyArch Dermatol Res199628884214258844118
   PubMed Web of Science ®Google Scholar
• MeasePJGoffeBSMetzJVanderStoepAFinckBBurgeDJEtanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trialLancet2000356922738539010972371
   PubMed Web of Science ®Google Scholar
• GottliebABMathesonRTLoweNA randomized trial of etanercept as monotherapy for psoriasisArch Dermatol2003139121627163214676082
   PubMed Web of Science ®Google Scholar
• LeonardiCLPowersJLMathesonRTEtanercept as monotherapy in patients with psoriasisN Engl J Med2003349212014202214627786
   PubMed Web of Science ®Google Scholar
• ElewskiBLeonardiCGottliebABComparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasisBr J Dermatol2007156113814217199580
   PubMed Web of Science ®Google Scholar
• NestorovIZitnikRLuddenTPopulation pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasisJ Pharmacokinet Pharmacodyn200431646349016222785
   PubMed Web of Science ®Google Scholar
• PappKATyringSLahfaMA global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reductionBr J Dermatol200515261304131215948997
   PubMed Web of Science ®Google Scholar
• PietrzakATZalewskaAChodorowskaGCytokines and anticytokines in psoriasisClin Chim Acta20083941–272118445484
   PubMed Web of Science ®Google Scholar
• TyringSGordonKBPoulinYLong-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasisArch Dermatol2007143671972617576937
   PubMed Web of Science ®Google Scholar
• MooreAGordonKBKangSA randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasisJ Am Acad Dermatol200756459860317113190
   PubMed Web of Science ®Google Scholar
• GordonKKormanNFrankelEEfficacy of etanercept in an integrated multistudy database of patients with psoriasisJ Am Acad Dermatol2006543 Suppl 2S101S11116488320
   PubMed Web of Science ®Google Scholar
• MössnerRSchönMPReichKTumor necrosis factor antagonists in the therapy of psoriasisClin Dermatol200826548650218755367
   PubMed Web of Science ®Google Scholar
• WeinbergJMAn overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasisClin Ther200325102487250514667953
   PubMed Web of Science ®Google Scholar
• NestorovIClinical pharmacokinetics of TNF antagonists: how do they differ?Semin Arthritis Rheum2005345 Suppl1121815852249
   PubMed Web of Science ®Google Scholar
• NestorovIClinical pharmacokinetics of tumor necrosis factor antagonistsJ Rheumatol Suppl200574131815742459
   PubMedGoogle Scholar
• Centers for Disease Control and PreventionHealth, United States, 2005Hyattsville, MD Available from: http://www.cdc.gov/nchs/data/hus/hus05.pdf#summary
   Google Scholar
• NaldiLChatenoudLLinderDCigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control studyJ Invest Dermatol20051251616715982303
   PubMed Web of Science ®Google Scholar
• McGowanJWPearceDJChenJRichmondDBalkrishnanRFeldmanSRThe skinny on psoriasis and obesityArch Dermatol2005141121601160216365269
   PubMedGoogle Scholar
• HerronMDHinckleyMHoffmanMSImpact of obesity and smoking on psoriasis presentation and managementArch Dermatol2005141121527153416365253
   PubMed Web of Science ®Google Scholar
• SterryWStroberBEMenterAInternational Psoriasis CouncilObesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and reviewBr J Dermatol2007157464965517627791
   PubMed Web of Science ®Google Scholar
• RoenigkHHJrAuerbachRMaibachHWeinsteinGLebwohlMMethotrexate in psoriasis: consensus conferenceJ Am Acad Dermatol19983834784859520032
   PubMed Web of Science ®Google Scholar
• StroberBGottliebALeonardiCPappKLevels of response of psoriasis patients with different baseline characteristics treated with etanerceptJ Am Acad Dermatol2006543 SupplAB220
   Web of Science ®Google Scholar
• TyringSGottliebAPappKEtanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trialLancet20063679504293516399150
   PubMed Web of Science ®Google Scholar
• SaracenoRSchipaniCMazzottaAEffect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasisPharmacol Res200857429029518400510
   PubMed Web of Science ®Google Scholar
• FeldmanSRKimballABKruegerGGWoolleyJMLallaDJahreisAEtanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trialJ Am Acad Dermatol200553588788916243150
   PubMed Web of Science ®Google Scholar
• KruegerGGLangleyRGFinlayAYPatient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trialBr J Dermatol200515361192119916307657
   PubMed Web of Science ®Google Scholar
• PallerASSiegfriedECLangleyRGEtanercept treatment for children and adolescents with plaque psoriasisN Engl J Med2008358324125118199863
   PubMed Web of Science ®Google Scholar
• MenterAGottliebAFeldmanSRGuidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicsJ Am Acad Dermatol200858582685018423260
   PubMed Web of Science ®Google Scholar
• GottliebABLeonardiCLGoffeBSEtanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy databaseJ Am Acad Dermatol2006543 Suppl 2S92S10016488335
   PubMed Web of Science ®Google Scholar
• DesaiSBFurstDEProblems encountered during anti-tumour necrosis factor therapyBest Pract Res Clin Rheumatol200620475779016979537
   PubMed Web of Science ®Google Scholar
• BrimhallAKKingLNLicciardoneJCJacobeHMenterASafety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trialsBr J Dermatol2008159227428518547300
   PubMed Web of Science ®Google Scholar
• KnightDMTrinhHLeJConstruction and initial characterization of a mouse-human chimeric anti-TNF antibodyMol Immunol19933016144314538232330
   PubMed Web of Science ®Google Scholar
• GottliebABMasudSRamamurthiRPharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgarisJ Am Acad Dermatol2003481687512522373
   PubMed Web of Science ®Google Scholar
• GottliebABEvansRLiSInfliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trialJ Am Acad Dermatol200451453454215389187
   PubMed Web of Science ®Google Scholar
• MenterAFeldmanSRWeinsteinGDA randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasisJ Am Acad Dermatol200756131.e1e1517097378
   PubMed Web of Science ®Google Scholar
• SchmittJZhangZWozelGMeurerMKirchWEfficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trialsBr J Dermatol2008159351352618627372
   PubMed Web of Science ®Google Scholar
• ReichKNestleFOPappKInfliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trialLancet200536694941367137416226614
   PubMed Web of Science ®Google Scholar
• BendtzenKGeborekPSvensonMLarssonLKapetanovicMCSaxneTIndividualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximabArthritis Rheum200654123782378917133559
   PubMed Web of Science ®Google Scholar
• KnightDMTrinhHLeJConstruction and initial characterization of a mouse-human chimeric anti-TNF antibodyMol Immunol19933016144314538232330
   PubMed Web of Science ®Google Scholar
• ScallonBCaiASolowskiNBinding and functional comparisons of two types of tumor necrosis factor antagonistsJ Pharmacol Exp Ther2002301241842611961039
   PubMed Web of Science ®Google Scholar
• ReichKGottliebABKimballALiSConsistency of infliximab response across subgroups of patients with psoriasis: integrated results from randomized controlled clinical trialsJ Am Acad Dermatol2006543 SupplAB215
   Web of Science ®Google Scholar
• GordonKBLangleyRGLeonardiCClinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension studyJ Am Acad Dermatol200655459860617010738
   PubMed Web of Science ®Google Scholar
• SauratJHStinglGDubertretLEfficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION)Br J Dermatol2008158355856618047523
   PubMed Web of Science ®Google Scholar
• MenterATyringSKGordonKAdalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJ Am Acad Dermatol200858110611517936411
   PubMed Web of Science ®Google Scholar
• CassanoNGalluccioADe SimoneCInfluence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE dataJ Biol Regul Homeost Agents200822423323719036225
   PubMed Web of Science ®Google Scholar
• SugiyamaHMcCormickTSCooperKDKormanNJAlefacept in the treatment of psoriasisClin Dermatol200826550350818755368
   PubMed Web of Science ®Google Scholar
• EllisCNKruegerGGAlefacept Clinical Study GroupTreatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytesN Engl J Med2001345424825511474662
   PubMed Web of Science ®Google Scholar
• RoggeMEllisCKruegerGPharmacokinetics of LFA3TIP (Amevive) in chronic plaque psoriasis patients during repeated once-weekly intravenous administrationJ Invest Dermatol19991124AB516
   Web of Science ®Google Scholar
• KruegerGGPappKAStoughDBA randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisJ Am Acad Dermatol200247682183312451365
   PubMed Web of Science ®Google Scholar
• LebwohlMChristophersELangleyRAn international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasisArch Dermatol2003139671972712810502
   PubMed Web of Science ®Google Scholar
• KruegerGGGottliebABSterryWKormanNVan De KerkhofPA multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasisJ Dermatolog Treat200819314615518569270
   PubMed Web of Science ®Google Scholar
• OrtonneJPKhemisAKooJYChoiJAn open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasisJ Eur Acad Dermatol Venereol200519555656316164708
   PubMed Web of Science ®Google Scholar
• CafardiJACantrellWWangWElmetsCAElewskiBEThe safety and efficacy of high-dose alefacept compared with a loading dose of alefacept in patients with chronic plaque psoriasisSkinmed200872677218327010
   PubMedGoogle Scholar
• MeasePJGladmanDDKeystoneECAlefacept in Psoriatic Arthritis Study GroupAlefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled studyArthritis Rheum20065451638164516646026
   PubMed Web of Science ®Google Scholar
• FinlayAYSalekMSHaneyJAlefacept Clinical Study GroupIntramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasisDermatology2003206430731512771471
   PubMed Web of Science ®Google Scholar
• EllisCNMordinMMAdlerEYEffects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trialAm J Clin Dermatol20034213113912553852
   PubMed Web of Science ®Google Scholar
• FeldmanSRMenterAKooJYImproved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasisBr J Dermatol2004150231732614996104
   PubMed Web of Science ®Google Scholar
• GordonKBVaishnawAKO’GormanJHaneyJMenterAAlefacept Clinical Study GroupTreatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell countsArch Dermatol2003139121563157014676071
   PubMedGoogle Scholar
• Alefacept package insert. http://www.fda.gov/cder/foi/label/2003/alefbio013003LB.pdf
   Google Scholar
• LoweNJGonzalezJBagelJCaroIEllisCNMenterARepeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacyInt J Dermatol200342322423012653922
   PubMed Web of Science ®Google Scholar
• LangewoutersAMBovenschenHJDe JongEMVan ErpPEVan De KerkhofPCThe effect of topical corticosteroids in combination with alefacept on circulating T-cell subsets in psoriasisJ Dermatolog Treat200718527928517852631
   PubMed Web of Science ®Google Scholar
• LangewoutersAMVan ErpPEDe JongEMVan De KerkhofPCThe added therapeutic efficacy and safety of alefacept in combination with other (systemic) anti-psoriatics in refractory psoriasisJ Dermatolog Treat200617636236917853311
   PubMed Web of Science ®Google Scholar
• LegatFJHoferAWackernagelANarrowband UV-B phototherapy, alefacept, and clearance of psoriasisArch Dermatol200714381016102217709660
   PubMedGoogle Scholar
• KruegerJGottliebAMillerBDedrickRGarovoyMWalickePAnti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell traffickingJ Invest Dermatol2000115233310951264
   PubMed Web of Science ®Google Scholar
• WertherWAGonzalezTNO’ConnorSJHumanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1J Immunol199615711498649958943405
   PubMed Web of Science ®Google Scholar
• LebwohlMTyringSKHamiltonTKA novel targeted T-cell modulator, efalizumab, for plaque psoriasisN Engl J Med2003349212004201314627785
   PubMed Web of Science ®Google Scholar
• LeonardiCLPappKAaxKBExtended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trialJ Am Acad Dermatol2005523 Pt 142543315761420
   PubMed Web of Science ®Google Scholar
• GordonKBPappKAHamiltonTKEfalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trialJAMA2003290233073308014679270
   PubMed Web of Science ®Google Scholar
• MenterAGordonKCareyWEfficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasisArch Dermatol20051411313815655139
   PubMed Web of Science ®Google Scholar
• GottliebABGordonKBLebwohlMGExtended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasisJ Drugs Dermatol20043661462415624744
   PubMedGoogle Scholar
• FretzinSCrowleyJJonesLYoungMSobellJSuccessful treatment of hand and foot psoriasis with efalizumab therapyJ Drugs Dermatol20065983884617039648
   PubMedGoogle Scholar
• StincoGPiccirilloFPatronePTreatment of palmoplantar pustular psoriasis with efalizumab: a quick response with early recurrenceEur J Dermatol2008181919218086606
   PubMed Web of Science ®Google Scholar
• WozelGVitezLPalmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximabActa Derm Venereol200888216917018311451
   PubMed Web of Science ®Google Scholar
• ColsmanACarrascosaJMFerrandizCSimonJCSuccessful treatment of recalcitrant palmoplantar psoriasis with efalizumabJ Eur Acad Dermatol Venereol20082291131113418410338
   PubMed Web of Science ®Google Scholar
• CohenDJScherschunLCase reports: practical experience with efalizumab in hand and foot psoriasisJ Drugs Dermatol20076121224123018189064
   PubMedGoogle Scholar
• VarmaRCafardiJACantrellWElmetsCSafety and efficacy of subcutaneously administered efalizumab in adults with moderate-to-severe hand and foot psoriasis: an open-label studyAm J Clin Dermatol20089210510918284264
   PubMed Web of Science ®Google Scholar
• BrunassoAMSalviniCMassoneCEfalizumab for severe palmoplantar psoriasis: an open-label pilot trial in five patientsJ Eur Acad Dermatol Venereol200923441541919207662
   PubMed Web of Science ®Google Scholar
• MenterAKosinskiMBresnahanBWPappKAWareJEJrImpact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasisJ Drugs Dermatol200431273814964744
   PubMedGoogle Scholar
• PappKACaroILeungHMGarovoyMMeasePJEfalizumab for the treatment of psoriatic arthritisJ Cutan Med Surg2007112576617374316
   PubMed Web of Science ®Google Scholar
• PappKACamisaCStoneSPSafety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. Part IIJ Cutan Med Surg20059631332316699903
   PubMed Web of Science ®Google Scholar
• WarkentinTEKwonPImmune thrombocytopenia associated with efalizumab therapy for psoriasisAnn Intern Med20051431076176216287807
   PubMed Web of Science ®Google Scholar
• ScheinfeldNEfalizumab: a review of events reported during clinical trials and side effectsExpert Opin Drug Safety200652197209
   PubMed Web of Science ®Google Scholar
• CostanzoATalamontiMSpalloneGEfficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapyDermatology2009218214615018971577
   PubMed Web of Science ®Google Scholar
• FDA Public Health Advisory: Updated Safety Information about Raptiva (efalizumab) http://www.fda.gov/cder/drug/advisory/efalizumab.htm
   Google Scholar
• LowesMATurtonJAKruegerJGBarnetsonRSPsoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case seriesBMC Dermatol20055916109173
   PubMedGoogle Scholar
• GaylorMLDuvicMGeneralized pustular psoriasis following withdrawal of efalizumabJ Drugs Dermatol200431777914964752
   PubMedGoogle Scholar
• BalatoALa BellaSGaudielloFBalatoNEfalizumab-induced guttate psoriasis. Successful management and re-treatmentJ Dermatolog Treat200819318218418569275
   PubMed Web of Science ®Google Scholar
• MenterAHamiltonTKTothDPTransitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb studyInt J Dermatol200746663764817550570
   PubMed Web of Science ®Google Scholar
• MaskatiaZKKooJRebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporineJ Drugs Dermatol20076994194417941368
   PubMedGoogle Scholar
• PappKATothDRosophLApproaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrenceBMC Dermatol20066917067371
   PubMedGoogle Scholar
• TortiDCFeldmanSRInterleukin-12, interleukin-23, and psoriasis: current prospectsJ Am Acad Dermatol20075761059106817706835
   PubMed Web of Science ®Google Scholar
• YawalkarNKarlenSHungerRBrandCUBraathenLRExpression of interleukin-12 is increased in psoriatic skinJ Invest Dermatol19981116105310579856816
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGFedorakRNA randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s diseaseGastroenterology200813541130114118706417
   PubMed Web of Science ®Google Scholar
• SegalBMConstantinescuCSRaychaudhuriARepeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging studyLancet Neurol20087979680418703004
   PubMed Web of Science ®Google Scholar
• KauffmanCLAriaNToichiEA phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasisJ Invest Dermatol200412361037104415610511
   PubMed Web of Science ®Google Scholar
• KruegerGGLangleyRGLeonardiCA human interleukin-12/23 monoclonal antibody for the treatment of psoriasisN Engl J Med2007356658059217287478
   PubMed Web of Science ®Google Scholar
• [No authors listed]Trial watch: novel biologic for psoriasis shows superiority over current best-sellerNat Rev Drug Discov2008711880881
   Web of Science ®Google Scholar
• PappKALangleyRGLebwohlMEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)Lancet200837196251675168418486740
   PubMed Web of Science ®Google Scholar
• LeonardiCLKimballABPappKAEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)Lancet200837196251665167418486739
   PubMed Web of Science ®Google Scholar
• GottliebAMenterAMendelsohnAUstekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trialLancet2009373966463364019217154
   PubMed Web of Science ®Google Scholar
• KimballABGordonKBLangleyRGSafety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trialArch Dermatol2008144220020718283176
   PubMedGoogle Scholar
• [No authors listed]Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic SocietyMMWR Recomm Rep200049RR-6151
   Google Scholar
• BransonBMHandsfieldHHLampeMACenters for Disease Control and Prevention (CDC)Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settingsMMWR Recomm Rep200655RR-1411716988643
   PubMedGoogle Scholar
• PappKABressinckRFretzinSSafety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trialInt J Dermatol200645560561416700803
   PubMed Web of Science ®Google Scholar
• DubertretLSterryWBosJDCLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trialBr J Dermatol2006155117018116792770
   PubMed Web of Science ®Google Scholar